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Summary
Pelizaeus-Merzbacher Disease (PMD) is an X-linked de-
velopmental defect of myelination affecting the central
nervous system and segregating with the proteolipopro-
tein (PLP) locus. Investigating 82 strictly selected spo-
radic cases of PMD, we found PLP mutations in 77%;
complete PLP-gene duplications were the most frequent
abnormality (62%), whereas point mutations in coding
or splice-site regions of the gene were involved less fre-
quently (38%). We analyzed the maternal status of 56
cases to determine the origin of both types of PLP mu-
tation, since this is relevant to genetic counseling. In the
22 point mutations, 68% of mothers were heterozygous
for the mutation, a value identical to the two-thirds of
carrier mothers that would be expected if there were an
equal mutation rate in male and female germ cells. In
sharp contrast, among the 34 duplicated cases, 91% of
mothers were carriers, a value significantly ( ,2x  9.20
) in favor of a male bias, with an estimation ofP ! .01
the male/female mutation frequency (k) of 9.3. More-
over, we observed the occurrence of de novo mutations
between parental and grandparental generations in 17
three-generation families, which allowed a direct esti-
mation of the k value ( ). Again, a significant malek  11
mutation imbalance was observed only for the dupli-
cations. The mechanism responsible for this strong male
bias in the duplications may involve an unequal sister
chromatid exchange, since two deletion events, respon-
sible for mild clinical manifestations, have been reported
in PLP-related diseases.
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Introduction
Pelizaeus-Merzbacher disease (PMD; MIM 312080), is
an X-linked defect of myelin formation affecting the
CNS. Originally described by Pelizaeus (1885), the clin-
ical syndrome was neuropathologically defined byMerz-
bacher (1910) as a diffuse hypomyelination of the CNS,
associated with an abnormally low number of mature
oligodendrocytes. The diagnosis is based on early/im-
paired motor development (during the first 3 mo of life)
characterized by severe hypotonia associated with nys-
tagmus and, later, the development of abnormal move-
ments and progressive spastic paraplegia. The severity
of the disease correlates with the level of motor per-
formance acquired between 5 and 10 years of age; in-
tellectual development is generally less affected (Boesp-
flug-Tanguy et al. 1996). Conduction velocity analysis
and magnetic resonance imaging (MRI) of the brain con-
firm that the dysmyelinating process is limited to the
CNS (Boulloche et al. 1986).
Several lines of evidence led to the identification of
the proteolipoprotein gene (PLP) as the causative locus
in PMD. This gene maps to the long arm of the human
X chromosome at Xq21-q22 (Mattei et al. 1986) and
encodes the two major myelin proteins of the CNS, the
proteolipoprotein (PLP) and its isoform, DM20. Several
point mutations in the coding and noncoding regions of
the PLP gene (for references, see Nave et al. 1996) have
been associated with the PMD phenotype but
account for only 10%–25% of the families analyzed.
However, linkage analysis established apparent genetic
homogeneity of families affected by PMD (Boespflug-
Tanguy et al. 1994). In fact, in most families in which
point mutations were not found, duplications of the en-
tire PLP gene are the causative mutation (Ellis et al.
1994; Inoue et al. 1996; Boespflug-Tanguy et al. 1997;
Sistermans et al. 1998).
Investigating 82 patients with sporadic PMD, we
found a PLPmutation in 63 (77%). Complete PLP-gene
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duplication was the most frequent abnormality (62% of
all mutations), and coding or splice-site point mutations
were found in 38% of all mutations. To determine the
origin of both types of PLP mutation, we analyzed the
maternal status in 56 cases. In addition, in the 17 three-
generation families in which the mother was a carrier
but the grandmother was not, we used haplotype seg-
regation analysis to determine the grandparental origin
of the mutations. We found that the de novo PLP du-
plications are of male origin in the large majority of
cases, whereas point mutations occur with the same fre-
quency in male and female gametes.
Families, Material, and Methods
Diagnosis and Selection of Families Affected by PMD
Patients with PMD were referred to us by neurope-
diatricians in several European countries because of our
interest in this condition. PMD was diagnosed by the
combination of a clinical PMD syndrome (hypotonia
and nystagmus of early onset, abnormal trunk and limb
movements, development of spastic paraplegia with py-
ramidal tract signs, and slow progression of the disorder)
in a male patient, with neurophysiological and MRI ev-
idence for a dysmyelinating process confined to the CNS
(Boespflug-Tanguy et al. 1994). Appropriate informed
consent was obtained from all families.
Two groups of subjects were used in this study: one
group of individuals, used to determine conditions for
the analysis of duplications, and one group of 82 families
affected by sporadic PMD, used to evaluate type and
origin of PLP abnormalities. The first group of subjects
comprised 45 normal males, 34 noncarrier females, and
18 obligate carrier mothers. Because of the absence of
any clinical signs in the great majority of females who
were heterozygous for PMD, the 34 noncarrier mothers
were identified by PLP haplotype segregation analysis
in 24 large families with PLP-duplicated probands. In
the same families, the 18 obligate carrier mothers were
selected if they had both an affected son and an affected
brother.
DNA Preparation
Genomic DNA was extracted by the guanidinium
chloride technique, as described elsewhere (Jeanpierre
1987).
Detection of PLP Point Mutations
DNA amplification using intronic primers flanking
each exon of the human PLP gene (Gencic et al. 1989)
was performed under standard conditions adapted for
each set of primers, as described elsewhere (Pham-Dinh
et al. 1991). Amplified DNA was sequenced on both
strands, with the same primers used in the amplification
reaction and the DNADye Terminator Cycle Sequencing
Kit (Applied Biosystems). Sequence analysis was per-
formed with an Applied Biosystems model 377 DNA
Sequencer.
Detection of PLP Duplications in Patients with PMD
A multiplex PCR-based test was performed to
coamplify exon IV from the PLP gene (Gencic et al.
1989) and exon IV from the CFTR gene (Dean et al.
1990). The use of one fluorescently labeled primer in
each set allowed the quantification of the multiplex
PCR products on an automated sequencer: PLP SG50,
5′-ACTCCAGGATCTCCCAGTTT-3′ (labeled with
6FAM); PLP 4R, 5′-CGTACCCTAACTCACCATAC-
3′; CFTR 4A, 5′-AGTCACCAAAGCAGTACAGC-3′
(labeled with 6FAM); and CFTR 4B, 5′-GCTATT-
CTCATCTGCATTCC-3′.
Preliminary experiments showed that, between 20 and
24 cycles, the amount of PCR product was directly pro-
portional to the copy number of the target sequence.
The reactions were performed in a PHC3 Techne ther-
malcycler in a final volume of 50 ml containing 100 ng
of genomic DNA, 0.2 mM each dNTP, 1.5 mM mag-
nesium chloride, 25 pmol of each primer, and 2 U of
Taq polymerase in the buffer provided by the manufac-
turer (Gibco BRL). Cycling conditions for each of the
21 cycles were 1 min at 91C, 45 s at 58C, and 1.30
min at 70C, the first cycle being preceded by one step
of 5 min at 94C and the last cycle being followed by
an extension program at 70C for 10min. Onemicroliter
of amplified DNA, mixed with agonized formamide and
loading buffer, was heat denatured and then loaded onto
a 12-cm 6.25% denaturing polyacrylamide gel. The in-
tensities of the bands corresponding to exons IV of the
CFTR and PLP genes were analyzed by an Applied Bio-
systems model 377 DNA Sequencer with the GENSCAN
and GENOTYPER software (Applied Biosystems). The
PLP-gene copy number in each individual was estimated
by comparison of the areas under the peaks for PLP
exon IV (PLP4) and CFTR exon IV (CFTR4).
We evaluated the quality of each experiment and the
reproducibility of results between experiments by ana-
lyzing three distinct control-DNA samples three times in
each experiment: one control was a mixture of eight
DNA samples from normal males, one was a mixture
of eight DNA samples from obligate carrier females, and
the third was a mixture of eight DNA samples from
noncarrier females. The final result was the ratio of the
PLP-gene dosage obtained for each PMD patient to the
PLP-gene dosage of a mix of eight DNA samples from
normal males analyzed in the same experiment.
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Figure 1 Detection of PLP duplication in 82 patients with sporadic PMD. The comparison of the fluorescence intensities of two PCR
products obtained by multiplex PCR (PLP exon 4 and CFTR exon 4) allows a discriminant analysis between one group of 45 normal males
(white histograms) and one of 34 noncarrier females (black hatched histograms). The analysis of the PLP4/CFTR4 ratio in 82 patients with
sporadic PMD (black histograms) resulted in two groups: one of 43 subjects that were similar to the normal male population and one of 39
subjects that were similar to the noncarrier female population. Each PLP4/CFTR4 result corresponds to the ratio of the PLP gene signal for
one subject to the PLP gene signal obtained with the mix of eight DNAs samples from normal males analyzed in the same experiment.
Detection of Heterozygous Carriers for the PLP
Duplication
To improve discrimination between normal females
and females who are heterozygous carriers of the PLP
duplication, two additional sets of primers were used:
one corresponding to exon 2 of the PLP gene (PLP2),
the other to exon 48 of the dystrophin gene (DMD48):
PLP2-SG 47, 5′-ATGAGCTACCTACTGGATGT-3′ (la-
beled with 6FAM); PLP2R, 5′-GGGCAGGTACTT-
ACACATTG-3′; DMD48MR, 5′-CCTGAATAAAGT-
CTTCTTTACCACAC-3′ (labeled with 6FAM); and
DMD48MF, 5′-AAGCTTGAAGACCTTGAAGAGC-3′.
Both pairs, PLP2-CFTR4 and PLP4-DMD48, were
coamplified in the same conditions as PLP4-CFTR4.
RFLP Markers
The genomic probe pXG-12 (DXS94), which detects
three PstI alleles with sizes of 6.5, 7.2, and 7.4 kb, was
used on Southern blots as described elsewhere (Boesp-
flug-Tanguy et al. 1994). Three other RFLP markers,
PLP exon IV/AhaII (Trofatter et al. 1990), DXS17/TaqI
(Kornreich et al. 1992), and PLP intron V/MspI (Wu et
al. 1987), were analyzed after a PCR reaction as de-
scribed elsewhere (Boespflug-Tanguy et al. 1994).
Multiallelic Markers
A PLP-intragenic microsatellite (Mimault et al. 1995)
and the two nearest known flanking extragenic micro-
satellites, DXS1191 and DXS1106 (Dib et al. 1996),
were used. The PCR-amplification reactions were per-
formed with one fluorescently labeled primer in each set
and a Gene Amp PCR System 9600 (Perkin Elmer) ac-
cording to standard procedure (Mimault et al. 1995).
Fragment analysis was performed on an Applied Bios-
ystems model 377 DNA Sequencer with the GENSCAN
and GENOTYPER software (Applied Biosystems).
Estimation of the Male/Female Ratio of Mutation
Frequencies
Two different methods were used to estimate themale/
female ratio of mutation frequencies (k). (1) Indirect es-
timation was performed in two-generation families ac-
cording to the method of Rosendaal et al. (1990),
described elsewhere for hemophilia A (Becker et al.
1996). This method determines the proportion of PMD
mothers who are carriers of the mutation, this propor-
tion being correlated to the k value. (2) Direct estimation
was performed in three-generation families in which the
mother was a carrier but the maternal grandmother was
not. The origin of the mutation in the maternal grand-
parental generation was determined by haplotype anal-
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Figure 2 Detection of PLP duplication in PMD carrier mothers. Results with two of the three different sets of primers used to perform
multiplex PCR (PLP4 / CFTR4 and PLP2 / CFTR4) are represented. Linear discriminant analysis with a nonparametric test revealed a hyperplane
that totally separated two classes of females, 18 obligate carriers (blackened diamonds) and 34 noncarrier mothers (black hatched squares),
without misclassifying any individual. It allowed testing of the 34 mothers of sporadic PLP-duplicated cases with an undetermined status (white
triangles): 31 were significantly identified as females with duplication, 3 as noncarriers.
ysis. In this case, k equals the number of cases of grand-
father (MGF) origin divided by the number of cases of
grandmother (MGM) origin (Haldane 1935). Differ-
ences between experimental and theoretical values were
evaluated by x2 analysis.
Results
Validation of Duplication Detection by Quantitative
Fluorescent Multiplex PCR
We first validated our PLP-gene duplication analysis
with quantitative fluorescent multiplex PCR by proving
that the method can distinguish between the presence of
one, two, or three copies of the PLP gene. First, to assess
the ability of the technique to distinguish between one
and two PLP-gene copies, we analyzed a population of
45 normal males and 34 noncarrier females (fig. 1). A
discriminant analysis between the male and female pop-
ulations, using the PLP4/CFTR4 ratio as the sole vari-
able, demonstrated a 100% classification of the individ-
uals into their respective groups (Mahalanobis
, , ). The mean ratio2distance  20.58 F  405 P ! .0001
was 0.99  0.12 for the male control population and
1.87  0.24 for the female one.
Second, to assess discrimination between two and
three PLP-gene copies, we analyzed the 34 noncarrier
females and the 18 obligate carrier mothers with three
different sets of primers. The mean  SD for the non-
carrier females was 1.87  0.24 for the PLP4/CFTR4
ratio, 1.84 0.18 for the PLP2/CFTR4 ratio and 0.94
 0.13 for the PLP4/DMD48 ratio. For the PLP-du-
plicated obligate carriers, the values were, respectively,
2.86  0.26, 2.69  0.18, and 1.39  0.13. Discri-
minant analysis was used to compare the population of
obligate PLP-duplicated carriers with the noncarrier fe-
males: the two populations were significantly distinct
when the PLP4/CFTR4 ratio was used as the sole var-
iable (Mahalanobis , ,2distance  19.24 F  266 P !
); however, discrimination clearly improved if.0001
PLP2/CFTR4 was introduced as a second variable (Ma-
halanobis , , ) and2distance  80.77 F  466 P ! .0001
PLP4/DMD48 as a third variable (Mahalanobis
, , ). Therefore, we2distance  140.81 F  538 P ! .0001
used all three measures to classify the two groups of
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Table 1
PLP-Gene Point Mutations
Family Number Mutation Site Type of Mutationa
99 Exon 2 C34Y
176 Exon 2 A38T
106 Exon 2 Y59C
191 Exon 2 C168R
107 Exon 3 G73R
21 Exon 4 Y174C
209 Exon 4 W180C
41 Exon 4 T182N
49 Exon 4 D202N
37 Exon 4 D202G
36 Exon 4 D202E
181 Exon 5 L209H
52 Exon 5 W211R
24 Exon 5 P215S
23 Exon 5 C227Y
133 Exon 6 Q233P
143 Exon 6 G245E
217 Exon 6 A247E
147 Exon 1 ATG-ACG
26 Intron 3 asp (GrT)
198 Intron 5 asp (GrA)
149 Intron 5 del 26 nuc
221 Intron 6 dsp (TrC)
182 Exon 6 ins TT fs F239r
a , splice site,asp  acceptor splice site dsp donor
, , and .ins  insertion del deletion fs frameshift
females for linear discriminant analysis with a nonpar-
ametric test (Geoffrey 1992). A hyperplane totally sep-
arated the two classes of females without misclassifying
any individual (fig. 2). The difference was significant, at
risks of .05 and .01. This computed hyperplane allowed
reliable classification of females of undetermined status.
Mutation Analysis in Sporadic Probands
Analysis of PLP4/CFTR4 ratio in the 82 PMD spo-
radic probands identified two groups (fig. 1). (1) In 39
cases the PLP4/CFTR4 values (1.87  0.21) were very
close to the control female values (1.87  0.24), sug-
gesting the presence of two copies of the PLP gene. The
duplication event was confirmed by the detection of het-
erozygosity in two affected males, by analysis of the PLP
intron 1 dinucleotide-repeat polymorphism (data not
shown). (2) In 43 patients, the PLP4/CFTR4 values
(0.95  0.10) were in the same range as those of the
control male population. These 43 patients were eval-
uated by direct sequencing of the seven PLP exons and
exon/intron junctions. Abnormalities were found in 24
cases (table 1). Of these, 18 (3/4) were missense muta-
tions in coding regions of the PLP gene. Therefore, we
could demonstrate a PLP-gene abnormality in 63 of the
82 cases of sporadic PMD (77%), 62% of the mutations
being gene duplications.
Detection of PLP Mutation in Mothers of Patients with
PMD
To determine the origin of both types of PLP muta-
tion, we examined the mothers of the 63 probands in
whom mutations were identified (table 2). Only 56
mothers were available for this analysis (table 2, samples
8–63). In the 34 duplicated cases, 31 mothers (91%)
were heterozygous for the duplication, as determined by
analysis of the ratios of PLP4/CFTR4, PLP2/CFTR4
(fig. 2), and PLP4/DMD48. In the 22 point mutation
cases, 15 mothers (68%) were carriers of the mutation.
No mutation was found in the mothers of 10 (18%)
probands (three duplications and seven point muta-
tions), suggesting that a de novo mutation occurred in
a germ cell of the patient’s mother.
Determination of De Novo PLP Mutations in the
Maternal Grandparental Germ Cells
To study more precisely the origin of PLP mutations,
we compared the number of de novo mutations in MGF
germ cells with those in the MGM. A blood sample from
the MGM was available for 25 (16 duplications and 9
point mutations) of the 46 families, in which the mother
was found to be carrier of the mutation (table 2, samples
39–63). In eight families (table 2, samples 56–63), both
the mother and the MGM were carriers of the mutation
(four duplications and four point mutations) such that
the origin of the PLP mutation remained undetermined.
In the remaining 17 families (table 2, samples 39–55),
the mutation was not detected in the MGM’s DNA,
indicating the occurrence of a de novo mutation between
the parental and grandparental generations. Using hap-
lotype segregation analysis in these 17 three-generation
families, we determined the grandparental origin of the
mutations (table 2). The de novo mutation originated
from the MGF germ cells in 11 of the 12 duplicated
families and from the MGM only in 1, leading to a sex
ratio of . Among the five fam-k MGF/MGM  11/1
ilies affected by point mutations, themutation originated
from the grandfather in four and from the grandmother
in one, resulting in a sex ratio of .k  4/1
Discussion
In Pelizaeus-Merzbacher disease, two types of PLP
mutations, point mutations and duplications of the PLP
gene, have been identified. Analyzing 82 index cases of
sporadic PMD, we found PLP-gene abnormalities in
77% of them, with duplication as the most common
cause of the disease (62% of those with gene abnor-
malities). Sistermans et al. (1998), in an analysis of 24
families affected by sporadic PMD, found a PLP ab-
normality in only 25% of cases (one point mutation and
Table 2
Results of the Mutation Analysis in the 63 Families with a PLP-Gene Abnormality
Sample
Family
Number Proband Mother MGM
Mutation
Origin
1 151 Duplication Not available Not available Unknown
2 153 Duplication Not available Not available Unknown
3 164 Duplication Not available Not available Unknown
4 192 Duplication Not available Not available Unknown
5 206 Duplication Not available Not available Unknown
6 147 Point mutation Not available Not available Unknown
7 182 Point mutation Not available Not available Unknown
8 39 Duplication Duplication/no abnormality Not available Unknown
9 40 Duplication Duplication/no abnormality Not available Unknown
10 51 Duplication Duplication/no abnormality Not available Unknown
11 55 Duplication Duplication/no abnormality Not available Unknown
12 60 Duplication Duplication/no abnormality Not available Unknown
13 74 Duplication Duplication/no abnormality Not available Unknown
14 79 Duplication Duplication/no abnormality Not available Unknown
15 118 Duplication Duplication/no abnormality Not available Unknown
16 121 Duplication Duplication/no abnormality Not available Unknown
17 122 Duplication Duplication/no abnormality Not available Unknown
18 136 Duplication Duplication/no abnormality Not available Unknown
29 187 Duplication Duplication/no abnormality Not available Unknown
20 188 Duplication Duplication/no abnormality Not available Unknown
21 189 Duplication Duplication/no abnormality Not available Unknown
22 227 Duplication Duplication/no abnormality Not available Unknown
23 106 Point mutation Point mutation/no abnormality Not available Unknown
24 133 Point mutation Point mutation/no abnormality Not available Unknown
25 143 Point mutation Point mutation/no abnormality Not available Unknown
26 149 Point mutation Point mutation/no abnormality Not available Unknown
27 176 Point mutation Point mutation/no abnormality Not available Unknown
28 191 Point mutation Point mutation/no abnormality Not available Unknown
29 61 Duplication No abnormality/no abnormality Unnecessary Maternal
30 94 Duplication No abnormality/no abnormality Unnecessary Maternal
31 105 Duplication No abnormality/no abnormality Unnecessary Maternal
32 49 Point mutation No abnormality/no abnormality Unnecessary Maternal
33 52 Point mutation No abnormality/no abnormality Unnecessary Maternal
34 181 Point mutation No abnormality/no abnormality Unnecessary Maternal
35 198 Point mutation No abnormality/no abnormality Unnecessary Maternal
36 209 Point mutation No abnormality/no abnormality Unnecessary Maternal
37 217 Point mutation No abnormality/no abnormality Unnecessary Maternal
38 221 Point mutation No abnormality/no abnormality Unnecessary Maternal
39 7 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
40 28 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
41 31 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
42 19 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
43 42 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
44 46 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
45 56 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
46 57 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
47 132 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
48 150 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
49 154 Duplication Duplication/no abnormality No abnormality/no abnormality MGF
50 23 Point mutation Point mutation/no abnormality No abnormality/no abnormality MGF
51 24 Point mutation Point mutation/no abnormality No abnormality/no abnormality MGF
52 26 Point mutation Point mutation/no abnormality No abnormality/no abnormality MGF
53 37 Point mutation Point mutation/no abnormality No abnormality/no abnormality MGF
54 96 Duplication Duplication/no abnormality No abnormality/no abnormality MGM
55 21 Point mutation Point mutation/no abnormality No abnormality/no abnormality MGM
56 15 Duplication Duplication/no abnormality Duplication/no abnormality Unknown
57 44 Duplication Duplication/no abnormality Duplication/no abnormality Unknown
58 50 Duplication Duplication/no abnormality Duplication/no abnormality Unknown
59 144 Duplication Duplication/no abnormality Duplication/no abnormality Unknown
60 36 Point mutation Point mutation/no abnormality Point mutation/no abnormality Unknown
61 41 Point mutation Point mutation/no abnormality Point mutation/no abnormality Unknown
62 99 Point mutation Point mutation/no abnormality Point mutation/no abnormality Unknown
63 107 Point mutation Point mutation/no abnormality Point mutation/no abnormality Unknown
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Table 3
Comparison Between the Numbers of Carrier and Noncarrier
Mothers Observed in the 56 PLP-Mutated Families and the
Values that Would Be Expected If There Were an Equal
Mutation Rate in Females and Males
Mutation Type (No.)
and Carrier Status
Experimental
Result
Theoretical
Value x2 Value
Point mutations (22):
Carrier 15 15
Noncarrier 7 7 )
Duplications (34):
Carrier 31 22.66 9.20
Noncarrier 3 11.33 P ! .01
Table 4
Comparison between the Numbers of PLP Mutations of MGM
and MGF Origin and the Values Would Be Expected If There
Were an Equal Mutation Rate in Females and Males
Type (No.) and
Grandparental Origin
of Mutations
Experimental
Result
Theoretical
Value x2 Valuea
Point mutations (5):
MGM 1 2.5 1.8
MGF 4 2.5 NS
Duplications (12):
MGM 1 6 8.33
MGF 11 6 P ! .01
a NS  not significant.
six duplications). The low percentage of PLP abnor-
malities found in their study probably reflects the mode
of selection of their patients. They relied on the finding
of severe hypomyelination on MRI, which is, however,
not specific for PMD and can be observed in numerous
acquired as well as hereditary diseases. Combination of
this MRI abnormality with the clinical features of PMD
and severe CNS conduction impairment on electrophy-
siological investigations (Boespflug-Tanguy et al. 1994,
1996) is necessary for the accurate diagnosis of PMD.
Various techniques have been proposed for detection
of PLP duplications, including Southern blotting (Ellis
et al. 1994; Sistermans et al. 1998), comparative mul-
tiplex PCR (CM-PCR) with ethidium bromide staining
for quantification (Inoue et al. 1996), and, more recently,
quantitative fluorescent multiplex PCR (Sistermans et al.
1998; Woodward et al. 1998) and FISH (Woodward et
al. 1998). The three different sets of multiplex PCR
primers we used in different amplification reactions
(PLP4/CFTR4, PLP2/CFTR4, PLP4/DMD48) allowed
clear discrimination between noncarrier mothers and ob-
ligate PLP-duplicated carriers. Using results with these
three primer pairs for linear discriminant analysis with
a nonparametric test, we obtained a hyperplane that
perfectly separated the two populations of females. This
computed hyperplane allows testing of females with un-
determined status. The accuracy and sensitivity of our
quantitative assay may be a consequence both of the fact
that the primers all correspond to nonpolymorphic cod-
ing regions of the different genes and of the use of only
two pairs of primers per multiplex PCR amplification.
To improve genetic counseling and to understand the
mechanism underlying PLP mutations, we determined
the origin of point mutation and duplication events by
two independent methods. In the families of patients
with point mutations, the number of carrier and non-
carrier mothers observed is not different from the the-
oretical values (2/3 carrier and 1/3 noncarrier mothers),
leading to a k value of 1 (table 3). In sharp contrast, the
experimental values for the duplication cases signifi-
cantly differ from the theoretical values (table 3), indi-
cating that the mutations are more frequent in male-
derived than in female-derived chromosomes (k 
). This strong male bias in duplication events was9.30
confirmed by the analysis of the grandparents (table 4).
As pointed out by A. C. Chandley (1991) in analyzing
de novo mutations, for most aneuploids there is a bias
toward maternal origin, whereas point mutations and
structural rearrangements, whatever their size, seem to
occur much more commonly in males. This appears to
be due to the large differences between oogenesis and
spermatogenesis. Indeed, large structural rearrange-
ments, which seem to be more frequent in males, can be
linked to the movements and contractions of the genome
observed during spermatid—but not oocyte—morpho-
genesis. For point mutations and small structural rear-
rangements, the active proliferation of spermatogonia,
which after puberty divide every 16 days throughout life,
may result in a large number of mutations that accu-
mulate with age, to produce the paternal age effects (Pen-
rose 1955). Moreover, both the lower overall sensitivity
of the female to mutation induction and the fact that
many millions of spermatozoa are produced for the fer-
tilization of a single oocyte would both contribute to
rendering the male more error-prone than the female
(Chandley 1991). These observations are in agreement
with our findings only concerning PLP duplications,
which occur preferentially, but not exclusively, on the
paternal chromosome during spermatogenesis. How-
ever, no grandpaternal age effect was observed in our
series of PLP-duplicated patients (unpublished data).
Investigation of the parental origin of the mutations
that cause different genetic disorders reveals a remark-
ably complex picture. For some, the nearly exclusive
paternal origin and the underlying mechanism are well
established. This is the case for point mutations in Apert
syndrome, which involves a CpG dinucleotide and
shows an extreme bias in favor of paternal origin, with
evidence for increasing incidence with increasing pater-
nal age (Moloney et al. 1996). Because DNA methyla-
tion is low in oocytes (Driscoll et al. 1990), mutations
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of this type may occur less frequently during oogenesis
than during spermatogenesis, where replication errors
may also accumulate over the life span of the individual.
Similarly, a male origin has been described for the in-
version process that disrupts the factor VIII gene at the
telomeric extremity of the long arm of the X chromo-
some (Rossiter et al. 1994). Here the proposed mecha-
nism is a flipping of the tip of the X chromosome, which
allows homologous pairing between copies of the A
genes localized both within and outside of the factor
VIII gene (Lakich et al. 1993). This can occur only dur-
ing male meiosis, when Xq is unpaired from its homolog.
Finally, the demyelinating peripheral neuropathy, Char-
cot-Marie-Tooth disease type 1A (CMT1A), is, in 77%
of cases, caused by a large duplication of the PMP-22
gene, whereas a milder form, hereditary neuropathywith
liability to pressure palsies (HNPP), is caused by a large
deletion of PMP-22. The nearly exclusive paternal origin
of this duplication process has been well documented
(Palau et al. 1993). Reiter et al. (1996) have proposed
that the CMT1A duplication and HNPP deletion are
reciprocal products of an unequal crossing-over event
between misaligned flanking CMT1A-REP repeats. In
this case, a mariner transposon–like element near the
hot spot of recombination may mediate strand-exchange
processes through cleavage by a transposase, the tran-
script of which is apparently produced in human testis
but not in ovaries. The recent analysis of 4 de novo
HNPP deletions and 36 CMT1A duplications (Lopes et
al. 1998) suggest that unequal crossing-over events,
which are frequently the cause of duplications, have a
paternal origin, whereas intrachromosomal rearrange-
ments, which are more frequently the cause of deletions,
are maternal. Thus, the sequences involved in recom-
bination are likely to be sex-dependent. However, the
restricted number of cases (four) with a proved maternal
origin do not allow this conclusion to be drawn with
certainty.
For other genetic disorders the results are less clear,
but a paternal bias is frequently—though not always—
observed. Moreover, the paternal bias tends to be
stronger for point mutations than for deletions, espe-
cially when they arise at CpG dinucleotides or involve
particular non-CpG transitions (Ketterling et al. 1993;
Grimm et al. 1994; Becker et al. 1996; Lazaro et al.
1996; Sommer and Ketterling 1996). The sex ratio seems
to be close to one in hemophilia B (Ketterling et al. 1993)
and one in Williams syndrome (Pe´rez-Jurado et al. 1996;
Urban et al. 1996) but is less clear for Duchenne mus-
cular dystrophy (Mu¨ller et al. 1992; Van Essen et al.
1992; Grimm et al. 1994) and even tends to suggest a
maternal origin in hemophilia A (Becker et al. 1996) and
neurofibromatosis type 1 (Lazaro et al. 1996).
In conclusion, in PMD patients, PLP duplications,
which are the most frequent type of causative mutation,
are mostly generated in male germ cells. The mechanism
responsible for such male bias may involve unequal sister
chromatid exchange, as has been proposed in other X-
linked genetic disorders in which both duplications and
deletions are found (Darras et al. 1987; Hu et al. 1990).
Indeed, in PLP-mutated patients, two deletion events
responsible for moderate clinical manifestations already
have been reported (Raskind et al. 1991; Nave et al.
1996). The extent of the duplication differs between
families (Woodward et al. 1998). Determination of the
duplication endpoints may explain whether flanking se-
quences mediate the recombination process.
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